Targeting Unmet Medical Needs
Our research is strategically aligned with high-impact therapeutic areas where precision medicine can transform patient outcomes.
Oncology
Targeted inhibitors, CAR-T expansions, and immunomodulatory biologics for solid and hematologic tumors.
Neurology
Disease-modifying therapies for ALS, Alzheimer’s, and rare neurodegenerative conditions using novel CNS delivery systems.
Rare Diseases
Orphan drug development leveraging gene editing, enzyme replacement, and patient-specific biomarker profiling.
Immunology
Biosimilars and next-gen biologics for autoimmune disorders, leveraging AI-driven epitope mapping.
Cardiovascular
Risk-reduction modalities, lipid-lowering siRNA therapies, and post-event cardiac regeneration protocols.
In Development & Approved
Track our candidates across all clinical phases. Data updated monthly in alignment with IND/CTA filings.
| Program Code | Therapeutic Area | Target / Modality | Phase | Next Milestone |
|---|---|---|---|---|
| AZP-492 | Oncology | PI3Kδ Inhibitor | Approved | Label Expansion Q3 2026 |
| AZP-815 | Neurology | Anti-Tau mAb | Phase III | Top-line Data Q4 2026 |
| AZP-603 | Rare Disease | AAV Gene Therapy | Phase II | Efficacy Readout Q2 2027 |
| AZP-550 | Immunology | IL-23 Antagonist | Phase III | Registration Trial Q1 2027 |
| AZP-722 | Cardiovascular | siRNA Lipid Lowering | Phase I | Dose Escalation Complete |
| AZP-118 | Oncology | BCL-2 Inhibitor | Approved | Commercial Launch |
Vertically Integrated Production
Our GMP-certified facilities ensure uncompromising quality, supply chain resilience, and rapid scale-up capabilities.
🏭 Biotherapeutics Hub (Switzerland)
Single-use bioreactor facilities producing monoclonal antibodies and cell/gene therapy vectors.
- 20,000L annual capacity
- FDA & EMA inspected
- Continuous flow chromatography
💊 Small Molecule Complex (Ireland)
High-potency API synthesis and solid dose formulation for oncology and rare disease programs.
- Containment Grade D
- QbD integrated workflows
- Automated tablet coating
🌐 Cold Chain Logistics
Temperature-controlled distribution network spanning 6 continents with real-time IoT monitoring.
- 2°C–8°C & -20°C compliance
- Blockchain traceability
- 99.8% on-time delivery
Patient Safety & Regulatory Excellence
We adhere to the highest global standards in clinical research, pharmacovigilance, and ethical manufacturing.
Clinical Trial Transparency
All studies registered on ClinicalTrials.gov and EU CTR. Results published regardless of outcome within 12 months of completion.
View Registry →Pharmacovigilance
24/7 safety monitoring aligned with ICH E2 guidelines. Automated adverse event detection and signal management.
Safety Reporting →AI & Data Governance
Fully auditable ML models for target identification. HIPAA/GDPR compliant data pipelines with zero third-party sharing.
Data Policy →Access & Affordability
Dynamic pricing models for low/middle-income markets. Expanded compassionate use and patient assistance programs.
Global Access →